Giuseppe A Ramirez
Overview
Explore the profile of Giuseppe A Ramirez including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
88
Citations
1322
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ramirez G, Cardamone C, Lettieri S, Fredi M, Mormile I
Clin Rev Allergy Immunol
. 2025 Feb;
68(1):13.
PMID: 39932658
Allergic and autoimmune disorders are characterised by dysregulation of the immune responses to otherwise inert environmental substances and autoantigens, leading to inflammation and tissue damage. Their incidence has constantly increased...
2.
Ramirez G, Calabrese C, Secci M, Moroni L, Gallina G, Benanti G, et al.
Pathogens
. 2024 Nov;
13(11).
PMID: 39599487
Systemic lupus erythematosus (SLE) is characterised by generalised immune dysfunction, including infection susceptibility. Infection-associated flares (IAFs) are common and might rapidly self-resolve, paralleling infection resolution, but their specific clinical phenotype...
3.
Ramirez G, Holopainen N, Gerosa M, Luca G, Bellocchi C, Arroyo-Sanchez D, et al.
Rheumatology (Oxford)
. 2024 Jul;
PMID: 39047157
Objectives: Cardiovascular involvement in systemic lupus erythematosus (SLE) is frequent but little is known about possible distinctive traits of SLE-related myocarditis (myoSLE) in comparison to patients with SLE (onlySLE) or...
4.
Tani C, Cardelli C, Zen M, Moroni L, Piga M, Ceccarelli F, et al.
J Rheumatol
. 2024 Jul;
51(11):1096-1101.
PMID: 38950957
Objective: To report real-world experience on the use of anifrolumab (ANI) in refractory systemic lupus erythematosus (SLE). Methods: The present study is a multicenter, retrospective study involving 9 Italian SLE...
5.
Bruschi M, Angeletti A, Prunotto M, Meroni P, Ghiggeri G, Moroni G, et al.
Autoimmun Rev
. 2024 Mar;
23(5):103535.
PMID: 38552995
Deposition of autoantibodies in glomeruli is a key factor in the development of lupus nephritis (LN). For a long time, anti-dsDNA and anti-C1q antibodies were thought to be the main...
6.
Ramirez G, Damanti S, Caruso P, Mette F, Pagliula G, Cariddi A, et al.
J Pers Med
. 2024 Jan;
14(1).
PMID: 38276237
Population aging and multimorbidity challenge health system sustainability, but the role of assistance-related variables rather than individual pathophysiological factors in determining patient outcomes is unclear. To identify assistance-related determinants of...
7.
Ramirez G, Tassi E, Noviello M, Mazzi B, Moroni L, Citterio L, et al.
Arthritis Rheumatol
. 2023 Dec;
76(5):739-750.
PMID: 38111123
Objective: The aim of this study was to assess whether circulating histone-specific T cells represent tools for precision medicine in systemic lupus erythematosus (SLE). Methods: Seroprevalence of autoantibodies and HLA-DR...
8.
Gueye M, Preziosa P, Ramirez G, Bozzolo E, Canti V, Margoni M, et al.
Mol Psychiatry
. 2023 Nov;
29(2):359-368.
PMID: 38036603
Choroid plexus (CP) enlargement is proposed as a marker of neuroinflammation in immune-mediated conditions. CP involvement has also been hypothesized in the immunopathology of systemic lupus erythematosus (SLE). We investigated...
9.
Paolino G, Ramirez G, Calabrese C, Moroni L, Bianchi V, Bozzolo E, et al.
Biomedicines
. 2023 Nov;
11(11).
PMID: 38001905
Refractory cutaneous manifestations constitute a significant unmet need in patients with cutaneous lupus (CLE), even in the setting of systemic lupus erythematosus (SLE) with otherwise good control of inflammatory manifestations....
10.
Capogrosso P, Bertini A, Pontillo M, Ferrara A, Cotelessa A, Carenzi C, et al.
Andrology
. 2023 Nov;
12(5):1137-1147.
PMID: 37987031
Background: Whether the observed lower total testosterone (tT) levels in male patients with COVID-19 are caused by a direct impact of SARS-CoV-2 infection or are collateral phenomena shared by other...